Therapies targeting innate immunity for fighting inflammation in atherosclerosis

Current Pharmaceutical Design

Volumn 21, Issue 9, 2015, Pages 1185-1195

  Mendel, Itzhak ^a   Yacov, Niva ^a   Harats, Dror ^a   Breitbart, Eyal ^a  

^a VBL Therapeutics   (Israel)

Author keywords

Atherosclerosis; Clinical trials; Monocytes

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARACHIDONATE 5 LIPOXYGENASE; CHEMOKINE; CHEMOKINE RECEPTOR; CHOLESTEROL; CYTOKINE; KAEMPFEROL; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TOLL LIKE RECEPTOR; ANTIINFLAMMATORY AGENT; AUTACOID;

ACUTE HEART INFARCTION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MIGRATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DISEASE COURSE; HUMAN; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; MONOCYTES;

EID: 84925872673     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141013133322     Document Type: Article

References (97)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25.
2. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013; 38: 1092-104.
3. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013; 13: 709-21.
4. Yona S, Kim KW, Wolf Y, et al. Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis. Immunity 2013; 38: 79-91.
5. Hettinger J, Richards DM, Hansson J, et al. Origin of monocytes and macrophages in a committed progenitor. Nat Immunol 2013; 14: 821-30.
6. Epelman S, Lavine KJ, Beaudin AE, et al. Embryonic and Adult-Derived Resident Cardiac Macrophages Are Maintained through Distinct Mechanisms at Steady State and during Inflammation. Immunity 2014; 40: 91-104.
7. Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013; 19: 1166-72.
8. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11: 155-61.
9. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-81.
10. Soehnlein O, Drechsler M, Doring Y, et al. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. Embo Mol Med 2013; 5: 471-81.
11. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2(-/-) mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-7.
12. Zhou Z, Subramanian P, Sevilmis G, et al. Lipoprotein-Derived Lysophosphatidic Acid Promotes Atherosclerosis by Releasing CXCL1 from the Endothelium. Cell Metab 2011; 13: 592-600.
13. Landsman L, Bar-On L, Zernecke A, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009; 113: 963-72.
14. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX(3)CR1(-/-) mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111: 333-40.
15. Wan WZ, Lim JK, Lionakis MS, et al. Genetic Deletion of Chemokine Receptor Ccr6 Decreases Atherogenesis in ApoEDeficient Mice. Circ Res 2011; 109: 374-81.
16. Manthey HD, Cochain C, Barnsteiner S, et al. CCR6 selectively promotes monocyte mediated inflammation and atherogenesis in mice. Thromb Haemostasis 2013; 110: 1267-77.
17. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014; Epub ahead of print.
18. van Breukelen-van-der-Stoep DF, Klop B, van Zeben D, Hazes JM, Castro Cabezas M. Cardiovascular risk in rheumatoid arthritis: how to lower the risk? Atherosclerosis 2013; 231: 163-72.
19. Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obe 2014; 23: 169-83.
20. Coumbe AG, Pritzker MR, Duprez, DA. Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med 2014; 127: 12-8.
21. Ridker PM. Psoriasis, inflammation, and vascular risk: a problem more than skin deep? . Eur Heart J 2010; 31: 902-4
22. Haringman JJ, Gerlag DM, Smeets TJ, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 2387-92.
23. Yellin M, Paliienko I, Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 1730-9.
24. Tak PP, Balanescu A, Tseluyko V, et al. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis 2013; 72: 337-44.
25. Bursill CA, Choudhury RP, Ali Z, Greaves DR, Channon KM. Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation 2004; 110: 2460-6.
26. Bursill CA, McNeill E, Wang L, et al. Lentiviral gene transfer to reduce atherosclerosis progression by long-term CC-chemokine inhibition. Gene Ther 2009; 16: 93-102.
27. Feige E, Yacov N, Salem Y, et al. Inhibition of monocyte chemotaxis by VB-201, a small molecule lecinoxoid, hinders atherosclerosis development in ApoE-/-mice. Atherosclerosis 2013; 229: 430-9.
28. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18Ffluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48: 1818-24.
29. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 2003; 23: 454-60.
30. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/-mice. Am J Pathol 2000; 157: 1819-24.
31. Erbel C, Dengler TJ, Wangler S, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol 2011; 106: 125-34.
32. Usui F, Kimura H, Ohshiro T, et al. Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. Biochem Bioph Res Co 2012; 420: 72-7.
33. Butcher MJ, Gjurich BN, Phillips T, Galkina EV. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res 2012; 110: 675-87.
34. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-25.
35. Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 734-42.
36. Garlanda C, Dinarello CA, Mantovani A. The Interleukin-1 Family: Back to the Future. Immunity 2013; 39: 1003-18.
37. Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome Activators Induce Interleukin-1 alpha Secretion via Distinct Pathways with Differential Requirement for the Protease Function of Caspase-1. Immunity 2012; 36: 388-400.
38. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1 beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 656-60.
39. Bhaskar V, Yin J, Mirza AM, et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein Edeficient mice. Atherosclerosis 2011; 216: 313-20.
40. Kamari Y, Shaish A, Shemesh S, et al. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1 alpha. Biochem Bioph Res Commun 2011; 405: 197-203.
41. Freigang S, Ampenberger F, Weiss A, et al. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1alpha and sterile vascular inflammation in atherosclerosis. Nat Immunol 2013; 14: 1045-53.
42. Toldo S, Schatz AM, Mezzaroma E, et al. Recombinant human interleukin-1 receptor antagonist provides cardioprotection during myocardial ischemia reperfusion in the mouse. Cardiovascular Drugs Ther 2012; 26: 273-6.
43. Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117: 2670-83.
44. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 2137-42.
45. Ohta H, Wada H, Niwa T, et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005; 180: 11-7.
46. Bissonnette R, Tardif JC, Harel F, Pressacco J, Bolduc C, Guertin MC. Effects of the Tumor Necrosis Factor-alpha Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis Results of a Randomized Controlled Trial. Circ Cardiovasc Imaging 2013; 6: 83-90.
47. Wang WY, Zhang J, Wu WY, et al. Inhibition of lipoproteinassociated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PloS One 2011; 6: e23425.
48. Hu MM, Zhang J, Wang WY, et al. The inhibition of lipoproteinassociated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin 2011; 32: 1253-8.
49. Wilensky RL, Shi Y, Mohler ER, 3rd, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-66.
50. Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 1172-82.
51. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370: 1702-11.
52. Seeger FH, Sedding D, Langheinrich AC, Haendeler J, Zeiher AM, Dimmeler S. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol 2010; 105: 389-97.
53. Seimon TA, Wang YB, Han S, et al. Macrophage deficiency of p38 alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest 2009; 119: 886-98.
54. Elkhawad M, Rudd JHF, Sarov-Blat L, et al. Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis. JACC Cardiovasc Imaging 2012; 5: 911-22.
55. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-50.
56. Piccinini AM, Midwood KS. DAMPening Inflammation by Modulating TLR Signalling. Mediat Inflamm 2010. doi: 10.1155/2010/672395.
57. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7.
58. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: Endogenous danger signaling. Mol Med 2008; 14: 476-84.
59. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Ph 2006; 290: C917-24.
60. Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A. Is serum amyloid A an endogenous TLR4 agonist? J Leukocyte Biol 2008; 83: 1174-80.
61. Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 2008; 181: 22-6.
62. Higashimori M, Tatro JB, Moore KJ, Mendelsohn ME, Galper JB, Beasley D. Role of Toll-Like Receptor 4 in Intimal Foam Cell Accumulation in Apolipoprotein E-Deficient Mice. Arterioscler Thromb Vasc Biol 2011; 31: 50-7.
63. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-84.
64. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10: 416-21.
65. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005; 115: 3149-56.
66. Shinohara M, Hirata K, Yamashita T, et al. Local overexpression of toll-like receptors at the vessel wall induces atherosclerotic lesion formation : Synergism of TLR2 and TLR4. Arterioscler Thromb Vasc Biol 2007; 27: 2384-91.
67. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111: 2654-61.
68. Ashida K, Miyazaki K, Takayama E, et al. Characterization of the expression of TLR2 (Toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb 2005; 12: 53-60.
69. Monaco C, Gregan SM, Navin TJ, Foxwell BMJ, Davies AH, Feldmann M. Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis. Circulation 2009; 120: 2462-9.
70. Huang CC, Liu K, Pope RM, et al. Activated TLR Signaling in Atherosclerosis among Women with Lower Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis. PloS One 2011; 6: e21067.
71. Mendel I, Feige E, Yacov N, et al. VB-201, an Oxidized Phospholipid Small Molecule, inhibits CD14-and TLR2-Dependent Innate Cell Activation and Constrains Atherosclerosis. Clin Exp Immunol 2014; 175: 126-37.
72. Mehrabian M, Allayee H, Wong J, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002; 91: 120-6.
73. Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006; 103: 8161-6.
74. Tardif JC, L'Allier P L, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010; 3: 298-307.
75. Benoit G, Cooney A, Giguere V, et al. International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev 2006; 58: 798-836.
76. Wang N, Yin R, Liu Y, Mao G, Xi F. Role of Peroxisome Proliferator-Activated Receptor-gamma in Atherosclerosis-An Update. Circ J 2011; 75: 528-35.
77. Takano H, Komuro I. Peroxisome Proliferator-Activated Receptor gamma and Cardiovascular Diseases. Circ J 2009; 73: 214-20.
78. Lim S, Despres JP, Koh KK. Prevention of Atherosclerosis in Overweight/Obese Patients-In Need of Novel Multi-Targeted Approaches. Circ J 2011; 75: 1019-27.
79. Li AC, Brown KK, Silvestre MJ, Willson TW, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in low density receptordeficient mice. J Clin Invest 2000; 106: 521-31.
80. Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice-Pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001; 21: 372-7.
81. Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 365-71.
82. Pelham CJ, Keen HL, Lentz SR, Sigmund CD. Dominant negative PPAR gamma promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. Am J Physiol Regul Integr Comp Physiol 2013; 304: R690-701.
83. Mizoguchi M, Tahara N, Tahara A, et al. Pioglitazone Attenuates Atherosclerotic Plaque Inflammation in Patients With Impaired Glucose Tolerance or Diabetes A Prospective, Randomized, Comparator-Controlled Study Using Serial FDG PET/CT Imaging Study of Carotid Artery and Ascending Aorta. JACC Cardiovasc Imaging 2011; 4: 1110-8.
84. Grosso AF, de Oliveira SF, Higuchi MD, Favarato D, Dallan LA, da Luz PL. Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetol Metab Syndr 2014; 6: 47.
85. Oh DY, Talukdar S, Bae EJ, et al. GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects. Cell 2010; 142: 687-98.
86. Calder PC. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res 2012; 56: 1073-80.
87. Calderon-Montano JM, Burgos-Moron E, Perez-Guerrero C, Lopez-Lazaro M. A Review on the Dietary Flavonoid Kaempferol. Mini-Rev Med Chem 2011; 11: 298-344.
88. Lin J, Rexrode KM, Hu F, et al. Dietary intakes of flavonols and flavones and coronary heart disease in US women. Am J Epidemiol 2007; 165: 1305-13.
89. Knekt P, Kumpulainen J, Jarvinen R, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002; 76: 560-8.
90. Kong L, Luo C, Li X, Zhou Y, He H. The anti-inflammatory effect of kaempferol on early atherosclerosis in high cholesterol fed rabbits. Lipids Health Dis 2013; 12: 115.
91. Lipszyc PS, Cremaschi GA, Zorrilla-Zubilete M, Bertolino M, et al. Niacin Modulates Pro-inflammatory Cytokine Secretion. A Potential Mechanism Involved in its Anti-atherosclerotic Effect. Open Cardiovasc Med J 2013; 20: 90-8.
92. Chai JT, Digby JE, Ruparelia N, Jefferson A, Handa A, Choudhury RP. Nicotinic Acid Receptor GPR109A Is Down-Regulated in Human Macrophage-Derived Foam Cells. PloS One 2013; 8: e62934.
93. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis through its receptor HCA(2) (GPR109A) expressed by immune cells. J Clin Invest 2011; 121: 1163-73.
94. Haynes R, Jiang LX, Hopewell JC, et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-91.
95. Masana L, Cabre A, Plana N. HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe? Atherosclerosis 2013; 229: 449-50.
96. Sharma M. Combination therapy for dyslipidemia. Curr Opin Cardiol 2011; 26: 420-3.
97. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extendedrelease niacin with laropiprant in high-risk patients. N Eng J Med 2014; 371: 203-12.